Comparison of the Molecular International Prognostic Scoring System (IPSS-M) and Revised International Prognostic Scoring System (IPSS-R) in predicting the prognosis of patients with myelodysplastic neoplasms treated with decitabine

• Published in: Oncologie (Paris, France) Vol. 26; no. 2; pp. 323 - 328
• Main Authors: Nguyen, Quang Hao, Vu, Minh Phuong, Tran, Tuan Anh, Duong, Quoc Chinh, Vu, Duc Binh, Nguyen, Ha Thanh, Bach, Quoc Khanh
• Format: Journal Article
• Language: English
• Published: De Gruyter 21.03.2024
• Subjects: decitabine; leukemia-free survival (LFS); Molecular International Prognostic Scoring System (IPSS-M); myelodysplastic neoplasms (MDS); prognosis; progression-free survival (PFS)
• DOI: 10.1515/oncologie-2023-0406
• ISSN: 1765-2839

Abstract Background Molecular International Prognostic Scoring System (IPSS-M) is a newly developed prognostic model for myelodysplastic neoplasms (MDS), but has not yet been used widely. In this study, we aimed to compare the IPSS-M with the traditional Revised International Prognostic Scoring System (IPSS-R) in predicting the prognosis of decitabine treated-MDS patients. Patients and methods This retrospective cohort study was conducted on 19 newly diagnosed MDS patients who were examined for 51 gene mutations and received decitabine treatment. The survival analysis, including overall survival (OS), progression-free survival (PFS), and leukemia-free survival (LFS), was performed using the Kaplan–Meier method. Comparisons between the risk groups were carried out according to the IPSS-R and IPSS-M models. Results Among the 19 MDS patients, 12 (63.2 %) showed myeloid gene mutations, with the highest frequency of mutations in ASXL1 , RUNX1 , SRSF2 , TET2 , and TP53 (15.8 %). Survival analysis found that the OS was significantly different between the risk groups of both IPSS-R and IPSS-M models, but the PFS and LFS showed significant differences between the risk groups in only the IPSS-M model. The PFS of the moderate, high, and very high-risk groups were 34.66, 25.00, and 15.33 months (p=0.031); respectively. The LFS of the moderate, high, and very high-risk groups were 39.20, 25.00, and 18.37 months, (p=0.039); respectively. Conclusions Our results found that IPSS-M was better than IPSS-R in predicting the PFS and LFS of decitabine-treated MDS patients, IPSS-M may be superior to IPSS-R in predicting the prognosis of MDS patients.